GlassScriptPhysician profile
Nathaniel T Ross
NPI 1417942707
$2,117.07
in general payments reported to CMS, 2019-2025
19 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $108 · 2021: $270 · 2022: $626 · 2023: $467 · 2024: $192 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $547.89 | 2019-2024 | Verquvo, Steglatro, Steglujan |
| Novo Nordisk INC | $306.77 | 2020-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $305.74 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $224.74 | 2022-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $145.30 | 2019-2020 | |
| Glaxosmithkline, LLC. | $75.04 | 2019-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $74.54 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.26 | 2019-2022 | |
| Covis Pharma Gmbh | $58.32 | 2022 | |
| Boston Scientific Corporation | $44.59 | 2019 | |
| Phadia US INC. | $43.93 | 2020-2022 | |
| Exact Sciences Corporation | $41.43 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $39.51 | 2023 | Gvoke Hypopen |
| Masimo Corporation | $38.99 | 2019 | |
| Lilly USA, LLC | $29.91 | 2022-2025 | Mounjaro, Zepbound |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $23.03 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $19.78 | 2020 | |
| Pfizer INC. | $15.83 | 2021 | |
| Mylan Specialty L.P. | $14.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.